Michael Jon Brown Sells 1,700 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the transaction, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Jon Brown also recently made the following trade(s):

• On Friday, May 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The stock was sold at an average price of $59.91, for a total transaction of $101,847.00.
• On Wednesday, April 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00.

DexCom Price Performance

Shares of DXCM stock traded down $1.93 during trading hours on Wednesday, hitting $71.23. The company’s stock had a trading volume of 4,301,335 shares, compared to its average volume of 5,344,921. The business has a fifty day moving average of $66.59 and a 200-day moving average of $67.76. The stock has a market cap of $27.49 billion, a price-to-earnings ratio of 30.44, a P/E/G ratio of 1.16 and a beta of 1.45. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company’s quarterly revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.32 earnings per share. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.58 EPS for the current year.

Institutional Trading of DexCom

Hedge funds have recently bought and sold shares of the company. Reflection Asset Management acquired a new stake in DexCom during the fourth quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new stake in DexCom during the first quarter worth approximately $25,000. CVA Family Office LLC boosted its position in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares during the last quarter. MCF Advisors LLC acquired a new stake in DexCom during the fourth quarter worth approximately $32,000. Finally, ORG Partners LLC boosted its position in DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the topic of several research reports. Truist Financial reiterated a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Citigroup reiterated a “buy” rating and issued a $84.00 price target (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. Benchmark initiated coverage on shares of DexCom in a research report on Monday, May 11th. They issued a “buy” rating and a $77.00 price target on the stock. Piper Sandler reiterated an “overweight” rating and issued a $88.00 price target (up from $75.00) on shares of DexCom in a research report on Monday. Finally, Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research report on Friday, May 1st. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $84.83.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.